Zongli ZHENG, Co-Founder, Chairman

Dr. Zongli ZHENG, the Co-Founder, Chairman, obtained his Ph.D. in Karolinska Institute and completed postdoctoral training at Harvard Medical School. Dr. ZHENG has over ten years of research experience in genome editing and has pioneered the development of precision genome editing technologies, including the high-fidelity CRISPR nucleases SpCas9-HF and SaCas9-HF; and the GUIDE-Seq methods for sensitive and unbiased CRISPR off-target analyses.